Trial Profile
Effect of idelalisib when given in combination with either rituximab, bendamustine or both in patients with indolent Non-Hodgkin Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 22 May 2015
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary) ; Bendamustine; Rituximab
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 22 May 2015 New trial record